top of page

South Africa SAHPRA Med. Dev Guideline: Site Master File (SMF) Requirements for Medical Device Wholesalers

The South African Health Products Regulatory Authority (SAHPRA) has published a new guidance document titled “Guideline for Preparation of a Site Master File (SMF) for Wholesalers of Medical Devices”. The guideline provides requirements for medical device wholesalers preparing a Site Master File (SMF) as part of medical device establishment licence applications in South Africa.

The guidance applies to wholesalers of medical devices, including In Vitro Diagnostic medical devices (IVDs), and focuses on ensuring that medical devices are stored, handled, and distributed according to acceptable quality assurance principles and good wholesaling practices.


Introduction to the Site Master File (SMF)

According to the SAHPRA guidance document, the Site Master File is a mandatory document required for medical device establishment licence applications. The SMF should contain information regarding wholesaling operations, quality systems, storage activities, distribution processes, and quality assurance controls performed at the site.

The document explains that the purpose of the SMF is to provide SAHPRA with a clear understanding of the wholesaler’s operations, organisational structure, premises, and compliance systems. The guideline also clarifies that a Quality Manual used for manufacturers or distributors may also be acceptable for wholesalers in certain situations.


General Requirements

The guidance states that the SMF must contain an issue number and effective date and should be updated whenever major operational changes or personnel changes occur. Updated SMFs are also required during licence renewal applications.

The SMF should include details such as:

  • Company and site information

  • Categories of medical devices handled

  • Storage and transportation conditions

  • Special handling precautions

  • Third-party service providers

  • Quality Management System (QMS) information

The guideline specifically highlights the importance of controls for hazardous, toxic, fridge-line, and radioactive medical devices.


Quality Management System and Personnel

A major focus of the guidance is the implementation of an effective Quality Management System (QMS). SAHPRA expects wholesalers to define quality policies, responsibilities, procedures, and quality assurance activities within the SMF.

The guidance also requires companies to describe self-inspection programmes and audit systems used to monitor compliance activities.

Personnel competency is another important area covered within the guidelines. Companies are expected to provide organisational charts, qualifications, responsibilities, and training information for key personnel involved in wholesaling activities.

The guideline additionally requires structured training programmes related to Good Warehouse Practice (GWP), operational procedures, and health and safety requirements.


Premises, Storage, and Equipment Controls

The guidance outlines expectations relating to premises, storage areas, ventilation systems, and equipment maintenance activities. Companies are expected to provide site plans and descriptions of wholesaling areas together with controls implemented to prevent unauthorised access.

Special attention is given to storage controls for sensitive products such as toxic, hazardous, fridge-line, and radioactive medical devices. The document also highlights the importance of temperature and humidity controls, cleaning procedures, pest control systems, and maintenance programmes.

These controls are intended to ensure that medical devices maintain their quality, safety, and performance throughout storage and distribution activities.


Stock Handling and Transportation

The guidance places strong emphasis on stock handling, traceability, and transportation controls. Companies are expected to describe procedures for receiving, storing, handling, and dispatching medical devices.

The guideline specifically requires wholesalers to explain how batch numbers, lot numbers, and expiry dates are managed throughout distribution activities. Inventory rotation systems such as FIFO should also be described.

SAHPRA additionally expects retained records to support full traceability from the Original Equipment Manufacturer (OEM) through to the customer.

Transportation controls should ensure product security, appropriate environmental conditions, and suitable handling of sensitive products during delivery activities.


Documentation, Complaints, and Internal Audits

The guidance also includes requirements relating to documentation systems and record management controls. Companies are expected to describe document preparation, approval, storage, revision, and retention procedures. The guideline further requires wholesalers to establish formal procedures for complaint handling and Field Safety Corrective Actions (FSCAs). Companies should explain how complaints are investigated, documented, and managed within the organisation.

Internal audit systems are also required to verify that wholesaling activities comply with regulatory requirements and internal procedures. Corrective actions should be implemented promptly where deficiencies are identified.


Conclusion

For medical device wholesalers and supply chain operators, the guideline highlights SAHPRA’s increasing focus on structured compliance systems and risk-based operational controls designed to ensure the quality, safety, and performance of medical devices distributed within South Africa.


References

Comments


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page